Fennec Pharmaceuticals Inc. Profile Avatar - Palmy Investing

Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patient…

Biotechnology
US, Research Triangle Park [HQ]
Major Shareholders · Proxy Ben. Owners

Shareholders

Breakdown
Fennec Pharmaceuticals Inc. can't present any analysts estimates at the moment detail analysis.
Intraday
Shares Outstanding
27,427,700
Volume
3,372
Volume on Avg.
122,203
Beneficial Owners Beta
SEC Source
Owner Shares Equivalence - $5.66 per share Last Form/Filing Last Transaction
10% Holder
- No data -
Officers/Directors Below 10%
- No data -
End of FENC's Analysis
CIK: 1211583 CUSIP: 31447P100 ISIN: CA31447P1009 LEI: - UEI: -
Secondary Listings
FENC has no secondary listings inside our databases.